NEXT GENERATION CONDOM CONTRACEPTION TO TACKLE SEXUALLY TRANSMITTED DISEASES & UNINTENDED PREGNANCIES
CASE STUDY (Filmed October 2023, June 2024)
Eudaemon Technologies
Australia
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
In 2022 Eudaemon Technologies was awarded AUD$1.5m in funding to advance the clinical trial of their next generation condom project, awarded by the Medical Research Future Fund (MRFF) funding from the Australian Government’s Clinical Translation and Commercialisation Medtech (CTCM) program, delivered by MTPConnect, and supported by MTAA.
Also, funding has come from NSW Health and The Office for Health and Medical Research.
According to Executive Chairman and Co-Founder Nick Northcott, the company has made significant progress in the past six months, including completing a pilot clinical trial involving 35 couples and achieving a major milestone.
“The completion of this Pilot Clinical Trial is a major milestone and value inflection point for the company. The Pilot Clinical data provides strong signal for safety, efficacy and consumer preference for Eudaemon’s Hydrogel Condom platform. We are now poised to move through scaling up our manufacturing, completing a Pivotal Clinical Trial prior to regulatory submission and then entering the market and commercialisation. A very exciting time for Eudaemon Tech as an Australian MedTech manufacturer.”, says Northcott.
Eudaemon Technologies is now focused on scaling up production and obtaining regulatory approval for commercialisation of their high-quality condoms. Once granted approval, the company is working towards scaling their manufacturing to produce the millions of units, with the ultimate aim to manufacture into the billions of high-quality condoms.
Eudaemon Technologies’ vision goes beyond the creation of a superior condom, as the company is ultimately contributing to an important global health cause. By assisting individuals in overcoming barriers to the consistent use of condoms through material innovation, the company endeavours to positively impact public health by mitigating the spread of STIs and reducing unplanned pregnancies on a global scale.
-
Junior Fellowship to develop vaccine for bacteria that cause ear infections
Dr Erin Brazel has a background in molecular and translational microbiology, with a focus on developing new ways of preventing and treating bacterial diseases. Recently Dr Brazel has been awarded a Junior Fellowship by the Passe & Williams Memorial Foundation.
The fellowship enables outstanding individuals to obtain postdoctoral training under the supervision of an experienced clinical or scientific researcher, with the view to establishing a research career in Otolaryngology, Head and Neck Surgery in Australia and/or New Zealand.
-
CASE STUDY Large scale genetic study finds link between Irritable Bowel Syndrome & cardiovascular system
Research published April 2024 in the journal Cellular and Molecular Gastroenterology and Hepatology sheds light on disease mechanisms common to irritable bowel syndrome (IBS) and cardiovascular diseases (CVD).
-
Biopsychosocial approaches to obsessive-compulsive, body image and eating disorders
Dr Nicola Acevedo is a Neuroscientist and Research Fellow with extensive expertise in developing novel therapeutics for neurological and psychiatric disorders, contributing to more than ten clinical trials. She specialises in brain stimulation and psychedelic treatments for obsessive-compulsive disorder (OCD) and related conditions, with a strong commitment to advancing personalised, evidence-based neurobiological therapies for severe psychiatric illness. Her approach integrates biopsychosocial and person-centred principles to improve treatment access and mental health outcomes.
